Connect Hearing, Inc. | |
5660 Monroe St, Unit 9 & 10, Sylvania, OH 43560-2733 | |
(419) 882-5950 | |
(419) 882-2361 |
Full Name | Connect Hearing, Inc. |
---|---|
Type | Facility |
Speciality | Hearing Aid Equipment |
Location | 5660 Monroe St, Sylvania, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356692594 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Connect Hearing, Inc. 750 N Commons Dr Ste 200, Aurora, IL 60504-7940 Ph: (630) 303-5380 | Connect Hearing, Inc. 5660 Monroe St, Unit 9 & 10, Sylvania, OH 43560-2733 Ph: (419) 882-5950 |
News Archive
A new type of drug therapy that is currently being tested in Canada could significantly reduce the death rate caused by the deadliest form of stroke. According to the Canadian Heart and Stroke Foundation, new developments in stroke research make it more important than ever that Canadians recognize and react to the warning signs of stroke.
Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents.
McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson's disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The Neuro, and Dr. Kalle Gehring in the Department of Biochemistry at the Faculty of Medicine, have discovered the three-dimensional structure of the protein Parkin.
While clinical trial results are being released regarding drugs intended to decrease amyloid production - thought to contribute to decline in Alzheimer's disease - clinical trials of drugs targeting other disease proteins, such as tau, are in their initial phases.
› Verified 1 days ago